FGF9 and metabolic dysfunction-associated steatohepatitis: Although FGF9 has already been reported to enhance the proliferation, invasion and migration of HCC cells in vitro,[30, 31, 32, 33, 34] however, the role of FGF9 in liver tumor formation in vivo, especially in NASH‐driven HCC, is still fully understood.